Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:50am, Tuesday, 24'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 29,873 Shares of Stock
04:48am, Tuesday, 24'th Feb 2026
Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) EVP Dana Aftab sold 29,873 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $4
Exelixis, Inc. $EXEL Shares Bought by Hillsdale Investment Management Inc.
06:10am, Monday, 23'rd Feb 2026
Hillsdale Investment Management Inc. grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 22.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commissi
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
03:45pm, Friday, 20'th Feb 2026
Exelixis' main franchise has helped it perform well in recent years. The biotech company is developing new, promising cancer drugs.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
10:46am, Friday, 20'th Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Christopher Senner Sells 34,278 Shares of Exelixis (NASDAQ:EXEL) Stock
06:50am, Friday, 20'th Feb 2026
Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) CFO Christopher Senner sold 34,278 shares of the business's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an av
Bob Oliver Sells 30,250 Shares of Exelixis (NASDAQ:EXEL) Stock
06:50am, Friday, 20'th Feb 2026
Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) Director Bob Oliver sold 30,250 shares of the firm's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $43.81,
Christopher Senner Sells 30,617 Shares of Exelixis (NASDAQ:EXEL) Stock
06:50am, Friday, 20'th Feb 2026
Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) CFO Christopher Senner sold 30,617 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of
Brenda Hefti Sells 18,669 Shares of Exelixis (NASDAQ:EXEL) Stock
06:06am, Friday, 20'th Feb 2026
Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) SVP Brenda Hefti sold 18,669 shares of the firm's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $44.0
A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts
10:16am, Monday, 16'th Feb 2026
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illinois Municipal Retirement Fund Boosts Position in Exelixis, Inc. $EXEL
04:30am, Saturday, 14'th Feb 2026
Illinois Municipal Retirement Fund grew its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 19.1% in the undefined quarter, according to the company in its most recent disclosure with the Secur
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Friday, 13'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or LQDA: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 12'th Feb 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value in
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
12:40pm, Thursday, 12'th Feb 2026
Exelixis Inc. NASDAQ: EXEL stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94 cents, wh
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
11:02am, Wednesday, 11'th Feb 2026
Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.
